Addition of GM-CSF Does Not Improve Response to Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

Thirty-three previously untreated patients with high risk CLL were treated before meeting standard criteria with alemtuzumab and rituximab. GM-CSF was added to the regimen to determine if it would improve treatment efficacy without increasing toxicity. High risk was defined as at least one of the fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Zent, Clive S., Wu, Wenting, Bowen, Deborah A., Hanson, Curtis A., Pettinger, Adam M., Shanafelt, Tait D., Kay, Neil E., Leis, Jose F., Call, Timothy G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4419690/
https://ncbi.nlm.nih.gov/pubmed/22853816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2012.717276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados